

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Nautilus Biotech S.A.	06/10/2009
RECEIVING PARTY DATA	
Name:	HANALL PHARMACEUTICAL CO., LTD.
Street Address:	400-1, Sangseo-dong, Daedeok-gu,
City:	Daejeon 306-120
State/Country:	KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12157150
CORRESPONDENCE DATA	
Fax Number:	(858)509-7460
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(858)509-7410
Email:	chicago.patents@klgates.com
Correspondent Name:	Stephanie Seidman
Address Line 1:	K&L Gates LLP
Address Line 2:	3580 Carmel Mountain Road, Suite 200
Address Line 4:	San Diego, CALIFORNIA 92130
ATTORNEY DOCKET NUMBER:	120239-00106 / 922K
NAME OF SUBMITTER:	Stephanie Seidman
Total Attachments: 33 source=Executed Nautilus to Hanall Assignment with attached Declaration and Chart of assigned patents #page1.tif source=Executed Nautilus to Hanall Assignment with attached Declaration and Chart of assigned patents #page2.tif source=Executed Nautilus to Hanall Assignment with attached Declaration and Chart of assigned patents #page3.tif source=Executed Nautilus to Hanall Assignment with attached Declaration and Chart of assigned patents #page4.tif source=Executed Nautilus to Hanall Assignment with attached Declaration and Chart of assigned patents #page5.tif	

CH \$40.00 12157150

500927337

PATENT
REEL: 023045 FRAME: 0259

[illegible]

ASSIGNMENT OF PATENTS RIGHTS

BETWEEN

NAUTILUS BIOTECH S.A., a French *Société Anonyme*, with a share capital of EUR 201,841.60 and a head office located at Pépinière Génopole Industries, 1 rue Pierre Fontaine - 91000 EVRY (FRANCE), registered with the Corporate Registry of Evry under number 428 988 778, represented by its liquidator, the SCP Yves Coudray - Christophe Ancel, 9, boulevard de l'Europe - 91050 Evry Cedex (FRANCE), nominated by a judgment of the Commercial Court of Evry of November 24, 2008 (hereinafter referred to as the "Liquidator");

Hereinafter referred to as the "Assignor",

AND

HANALL PHARMACEUTICAL Co. Ltd., a Korean Company, with a stated capital of EUR 15,1 million and a head office located at 11-10 Sincheon-Dong Songapa-Gu, SEOUL (KOREA), registered with the Corporate Registry of Daejeon under number 164111-0000397, represented by its CEO and President, Mr. Kim Sung-Wuk, duly authorized hereunder;

Hereinafter referred to as the "Assignee",

Jointly referred to as the "Parties".

IT IS CONSIDERED AS FOLLOWS:

Pursuant to a judgment rendered by the Commercial Court of Evry on July 21, 2008, a bankruptcy proceeding was opened against the Assignor. On November 24, 2008, the Commercial Court ordered the liquidation of the Assignor and appointed the SCP Yves Coudray - Christophe Ancel, duly represented by Maître Christophe Ancel, as Liquidator of Nautilus Biotech.

The Assignee then transmitted an offer to the Liquidator in order to purchase the entire Assignor's patent portfolio.

By a court order rendered on February 17, 2009, and pursuant to Article L 642-19 of the French Commercial Code, the Commercial Court of Evry ordered the assignment of all the patents and patent applications covered by the compulsory liquidation of the Assignor to the Assignee (hereinafter the "Order").

In this perspective, the Assignor assigns by this agreement any patents and patent applications it holds (hereinafter the "Patents"), as listed under Schedule 2 (Patents), including, but not limited to any and all rights to inventions that can be derived from the Patents, any and all scientific documents (including research materials/data in digital format as found in Nautilus Biotech's computers and servers), and any and all cells banks directly or indirectly attached to the Patents (hereinafter the "Complementary Documents").

According to the Order, the Assignor assigns the Patents and Complementary Documents to the Assignee, which wishes to acquire them from the Assignor.



CONSEQUENTLY, IT IS AGREED AS FOLLOWS:

Article 1 – Transfer of Patents and Complementary Documents - Declaration of Transfer

The Assignor hereby assigns with full title guarantee to the Assignee the Patents and Complementary Documents free and clear of any licenses, liens, pledges, security interests, prior assignments or any other encumbrances, with effect at the date of signature of the present agreement.

The Parties hereby sign the joint Declaration of Transfer attached hereto as Schedule 1.

The Assignor states that he assigns any Patents, which are listed under Schedule 2, and any Complementary Documents it holds.

The Assignor hereby agrees to sign, upon the Assignee's request and at the Assignee's costs, any and all documents and any further deeds and to take all such steps as are necessary or reasonably required to formalise the transfer to the Assignee of the Patents.

Article 2 – Price

The transfer of the Patents and Complementary Documents, held by the Assignor to the Assignee shall be paid to the Liquidator by the mean of EUR 400,000 cheque payable to "SCP Yves Coudray – Christophe Ancel".

Article 3 – Extension of the scope of the assignment

In the eventuality whereby a patent or patent application held by the Assignor would have not been listed in Schedule 2, it would be retroactively included in the present agreement at no cost for the Assignee, by way of an amendment under the conditions set forth in Article 9.

Article 4 – Proceedings

From the date of signature of this assignment agreement, the Assignee shall have the right to bring proceedings against any third party in respect of the Patents (including proceedings against any third party for past and future infringement of the Patents or for passing off).


Article 5 – Costs and fees

All costs and fees relating to the maintenance and prosecution of the Patents, including but not limited to, attorney fees, registration fees, maintenance fees, and official fees, that were incurred prior to the date of the Order, shall be borne by the Assignor.

All costs and fees relating to this agreement, notably to the perfection of the transfer of the Patents before any competent Intellectual Property Offices shall be borne by the Assignee.

Article 6 - Notices

Whenever written notices are required under the provisions of this agreement, such written notices shall be sent by registered mail with return receipt requested, addressed to the Parties at their



respective address set forth in the preamble to this agreement or to such other address as either party may hereafter communicate to the other in writing.

Article 7 - Language

The language of communication between the Parties under this agreement shall be the English language.

Article 8 - Entire agreement

This agreement, including Schedules, is the entire agreement between the Parties with respect to the subject matter hereof.

Article 9 - Amendments

This agreement may not be altered or amended except by a written agreement duly executed by both Parties.

Article 10 - Waivers

None of the terms or conditions of this agreement shall be deemed or construed to have been waived by either party unless such waiver is set forth in a written instrument properly signed by such party.

Article 11 - Severability

In the event that any provision or any portion of any provision contained in this agreement is unenforceable, the remaining provision and, in the event that a portion of any provision is unenforceable, the remaining portion of such provision, shall nevertheless be carried into effect, provided, however, that in such case the Parties oblige themselves to use their best efforts to achieve the purpose of the invalid provision by a new legally valid stipulation.

Article 12 - Governing law

This agreement shall be governed by and construed in accordance with the laws of France.

Article 13 - Settlement of disputes

The Parties agree to resolve any dispute which may arise between them as a result of, in connection with or related to this agreement, by diligent negotiation in good faith.


Should any such dispute between the Parties remain unresolved, the Parties shall, within thirty (30) days of the written request of one of them to do so, appoint a conciliator, whose mission will be to try to bring the Parties to an agreement.

Should no agreement be reached through the intervention of the conciliator within thirty days from his appointment, either party shall be entitled to bring the case exclusively before the Tribunal of Grande Instance of Paris.



Done in Paris on 10/06/2009


in two (2) original copies



HANALL PHARMACEUTICAL Co. Ltd.

Name: Sung-Wuk Kim

Title: CEO



NAUTILUS BIOTECH S.A.

Schedules:

1. Declaration of transfer
2. Chart of the assigned Patents



SCHEDULE 1
DECLARATION OF TRANSFER

The Undersigned:

NAUTILUS BIOTECH S.A., a French *Société Anonyme*, with a share capital of EUR 201,841.60 and a head office located at Pépinière Génopole Industries, 1 rue Pierre Fontaine - 91000 EVRY (FRANCE), registered with the Corporate Registry of Evry under number 428 988 778, represented by its liquidator, the SCP Yves Coudray - Christophe Ancel, 9, boulevard de l'Europe - 91050 Evry Cedex (FRANCE), nominated by a judgment of the Commercial Court of Evry of November 24, 2008;


Assignor

Confirm hereby that was assigned to the Assignee, HANALL PHARMACEUTICAL Co. Ltd., a Korean Company, with a stated capital of EUR 15,1 million and a head office located at 11-10 Sincheon-Dong Songapa-Gu, SEOUL (KOREA), registered with the Corporate Registry of Daejeon under number 164111-0000397, represented by its CEO and President, Mr. Kim Sung-Wuk, duly authorized hereunder, as of 2009, the Patents attached hereto;


And give hereby an irrevocable power of attorney to Hanall Pharmaceutical and each of the persons designated by Hanall Pharmaceutical;

Authorising them to take all necessary steps to do all that is necessary or useful for the registration of the transfer of the Patents and the protection thereof.

Signed in Paris, on 10/06/2009



NAUTILUS BIOTECH S.A.



HANALL PHARMACEUTICAL Co. Ltd.
Name: Sung-Wuk Kim
Title: CEO

SCHEDULE 2

Chart of the assigned Patents

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-PRV	High Throughput Directed Evolution By Rational Mutagenesis	60/315,382	08/27/01 (SMALL)	EXPIRED PROVISIONAL
US-CON	High Throughput Directed Evolution By Rational Mutagenesis	10/022,249 PUBLICATION NO.: US-2003-0134351-A1 DATE: 07/17/2003	12/17/01 (SMALL)	Pending RESPONSE TO OFFICE ACTION FILED 4/16/09 04/09/09 – Letter to Client Requesting Instructions Regarding Response to Official Action 04/02/09 – Email and Letter to Client Urgent Reminder Requesting Instructions for Response to Office Action Ultimate Due Date 04/16/09 03/06/09 – Email and Letter to Client 3 rd Reminder Request Instructions and Retainer for Response to Office Action 02/13/09 – Email and Letter to Client 2 nd Reminder Request Instructions and Retainer for Response to Office Action 01/09/09 – Email and Letter to Client Reminder Request Instructions and Retainer for Response to Office Action 10/27/08 – Email and Letter to Client Forward Office Action Due 01/16/09; Drop 04/16/09; Request Retainer 10/16/08 - PTO Mailed Office Action due 01/16/09 Drop 04/16/09 Utility Filed from Provisional 60/315,382 (911)
WO-PAT	High Throughput Directed Evolution By Rational Mutagenesis	PCT/IB02/03921 PRIORITY NOS: 60/315,382 10/022,249 PUBLICATION NO.: WO 03/023032 DATE: 02/03/03	08/16/02 (PRIORITY) 08/27/01 12/17/01	PCT Completed – Filed EP Only (02798018.4); National Filing in EP Only ----- Ep Application Filed by Cabinet Ores
EP-PAT	High Throughput Directed Evolution By Rational Mutagenesis	European Patent App. No.: 02798018.4 Based on (PCT/IB02/03921)	International Filing Date: 08/16/2002	ABANDONED

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-PAT	Mutant Recombinant Adeno-Associated Viruses	10/022,390 PUBLICATION NO.: US-2003-0129203-A1 DATE: 07/10/2003	12/17/01 (FILED SMALL)	ABANDONED
WO-PAT	Mutant Recombinant Adeno-Associated Viruses	PCT/IB02/04087 PRIORITY NOS: 60/315,382 10/022,390 PUBLICATION NO.: WO 03/018820	08/16/02 (PRIORITY) 08/27/01 12/17/01 PUBLICATION DATE: 03/06/03	PCT Completed - No National/Regional Filings
US-PRV	High Throughput Directed To Evolution Of Nucleic Acids By Rational Mutagenesis	60/360,085	02/25/02 (SMALL)	EXPIRED PROVISIONAL
US-PAT	High Throughput Directed To Evolution Of Nucleic Acids By Rational Mutagenesis	10/375,192 PUBLICATION NO.: US-2003-0224404-A1 DATE: 12/04/2003	02/24/03 (SMALL)	ABANDONED
US-PRV	Rational Evolution Of Cytokines For Higher Stability, Encoding Nucleic Acid Molecules And Related Applications	60/409,898	09/09/02 (SMALL)	EXPIRED PROVISIONAL
US-PRV	Rational Evolution Of Cytokines For	60/457,135	03/21/03	EXPIRED PROVISIONAL

PATENT

REEL: 023045 FRAME: 0268

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-PAT	Higher Stability, Encoding Nucleic Acid Molecules And Related Applications Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	10/658,834 PUBLICATION NO.: US-2004-0132977-A1 DATE: 07/08/2004	(SMALL) 09/08/03 (SMALL)	PENDING RESPONSE TO OFFICE ACTION TO BE FILED 4/17/09 01/28/09 – Email and Letter to Client Reminder Request Instructions and Retainer for Preparing and Filing Response to Final Office Action 11/19/08 – Email and Letter to Client Forward Final Office Action due 02/13/09; Drop 05/13/09, Request Retainer 11/13/08 - PTO Mailed Final Office Action Due 02/13/09, Drop 05/13/09 Utility Application Filed from Provisionals 60/409,898 and 60/457,135
US-CON	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/176,830 PUBLICATION NO. US-2006-0020116-A1 DATE: 01/26/2006	07/06/05 (LARGE)	LAPSED 04/20/09 – Email from FA to let NOT file Notice of Appeal and to let application lapse 03/31/09 – Email and Letter to Client Urgent Reminder Request Instructions for Response to Final Office Action Ultimate Due Date 04/28/09 02/12/09 – Email and Letter to Client 2 nd Reminder Request Instructions and Required Retainer for Response to Final Office Action 01/12/09 - Email and Letter to Client Reminder Final Office Action Due 01/28/09, Drop 04/28/09, Request Instructions and Retainer 11/04/08 – Email and Letter to Client Forward Final Office Action Due 01/28/09, Drop 04/28/09, Request Retainer 11/04/08 – Email to Client Electronic Copy of Final Office Action, Request Retainer 10/28/08 - PTO Mailed Office Action Due 01/28/09, Drop 04/28/09 Continuation of 10/658,834 Filed 9/8/03
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/703,610 US PUBLICATION NO.:	02/06/07	ABANDONED

PATENT

REEL: 023045 FRAME: 0269

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	US-2008-0075672-A1 3/27/08 11/704,141	02/07/07	Pending Response to Non-Final Office Action Deadline: 07/03/09; Drop 10/03/09 04/10/09 – Letter and Email to Client Forward Copy of Office Action 04/03/09 – PTO Mailed Non-Final Office Action Dated 04/03/09; Response Due 07/03/09; Drop 10/03/09 01/05/09 - Return Receipt Postcard Received for Election and Preliminary Amendment 12/30/08 – Email and Letter to Client Forward Filed Election and Preliminary Amendment 12/29/08 – Filed Election and Preliminary Amendment 05/15/08 - Divisional of 10/658,834
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/656,921 PUBLICATION NO. US-2007-0254838-A1 DATE: 11/01/07	1/22/07	ABANDONED
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/706,088 PUBLICATION NO.: US-2007-0172459-A1 DATE: 07/26/07	2/13/07	Pending Response to Office Action Due: 02/12/09; Drop 05/12/09 03/26/09 – Letter to Client (HanAll) – 3 rd Reminder Response to Office Action Next Due Date 04/12/09 and Drop Date 05/12/09; Requesting Instructions 02/27/09 –Email to Client 2 nd Reminder Requesting Instructions and Required Retainer for Response to Office Action 01/28/09 – Email and Letter to Client Reminder Request Instructions and Retainer for Preparing and Filing Response to Office Action

PATENT

REEL: 023045 FRAME: 0270

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				11/19/08 – Email from Client Confirmed Receipt of Email Dated 11/18/08 11/18/08 – Letter to Client Forward Notice of Publication 11/18/08 – Email and Letter to Client Forward Office Action due 02/12/09, Drop 05/12/09, Requesting Retainer 11/12/08 - PTO Mailed Non-Final Office Action due 02/12/09, Drop 05/12/09 Divisional of 10/658,834
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/707,014 PUBLICATION NO. 2007-0224665-A1 DATE: 09/27/07	2/14/07	PENDING –NON-FINAL OFFICE ACTION DUE 03/24/09; DROP 06/24/09 12/31/08 – Email and Letter to Client Forward Office Action; Request Instructions and Retainer 12/24/08 – PTO Mailed Non-Final Office Action Due 03/24/09; Drop 06/24/09 10/10/08 - Return Receipt Postcard Received 10/09/08 – Letter to Client Forward Filed Election and Preliminary Amendment 10/03/08 – Filed Election and Preliminary Amendment 09/03/08 – PTO Mailed Restriction Requirement Due 10/03/08 Divisional of 10/658,834
US-DIV	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	11/825,604	7/5/07	Pending Office Action Deadline: 02/25/09; Drop 05/25/09 03/23/09 – Email and Letter to Client (HanAll) Second Reminder Request Instructions for Response to Office Action Due 03/25/09; Drop 05/25/09 02/13/09 – Email and Letter to Client Request Instructions and Required Retainer for Response to Office Action 12/03/08 – Email and Letter to Client Forward Office Action 11/25/08 – PTO Mailed Office Action Due 02/25/09, Drop 05/25/09 Divisional Of 10/658,834
US-PAT	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And	12/082,365	04/09/08	PENDING – AWAIT FIRST OFFICE ACTION

PATENT

REEL: 023045 FRAME: 0271

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
	Encoding Nucleic Acid Molecules			02/05/09 -- PTO Mailed Updated Filing Receipt 01/28/09 -- Email and Letter to Client Forward Notice of Acceptance of POA 01/20/09 - Return Receipt Postcard Received for Response to Notice to File Corrected Application Papers 01/14/09 -- Letter and Email to Client Forward Notice to File Corrected Application Papers and Filed Response to Notice to File Corrected Application Papers 01/12/09 -- Filed Response to Notice to File Corrected Application Papers 11/13/08 - PTO Mailed Notice to File Corrected Application Papers Due 01/13/09; Drop 06/13/09
US-PAT	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	12/082,389 PUBLISHED: US-2009-0053147-A1 PUBLICATION DATE: 02/26/09 APPLICANTS: Renee Gantier Manuel Vega Lila Driftniti Thierry Guyon	04/09/08	PENDING - AWAITING OFFICE ACTION 02/26/09 - PTO Mailed Notice of Publication 01/28/09 -- Email and Letter to Client Forward Notice of Acceptance of POA
US	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	12/157,150	06/26/08	PENDING -- AWAIT FIRST OFFICE ACTION 02/13/09 -- Email and Letter to Client Forward Updated Filing Receipt 02/06/09 -- PTO Mailed Updated Filing Receipt 01/30/09 - Received Return Receipt Postcard for Response to Notice to File Corrected Application Papers 01/23/09 - Email and Letter to Client Forward Notice to File Corrected Application Papers and Response

PATENT

REEL: 023045 FRAME: 0272

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
WO-PAT	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	PCT/IB03/04347 PCT Publication No. WO 2004/022593 Priority Appln Nos: 60/409,898 60/457,135	09/08/03 PCT Publication Date 03/18/04 Priority Dates 09/09/02 03/21/03	PCT Completed – Corresponding Filings in EUROPE and CANADA
EP-PAT	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	03794017.8 Based on PCT/IB2003/004347	09/08/03 (PCT)	Pending – Awaiting further Official Action and/or Allowance <i>Regional Phase of PCT/IB03/004347</i> 2009 Renewal Fee (7 th Year) Deadline: 09/08/09 Last Response/Amendment filed per 2 nd OA filed with EPO 3/11/2009 (amended claims 1-29) 03/11/09 - Email from Dr. Park (Hanall Pharmaceutical Co.) - Will Pay Retainer; Will Decide Direction for Other Patents and Inform Soon 03/11/09 - Email from FA Reporting Filing of Response; Copy of Response and Amended Claims Attached
CA-PAT	Rational Evolution Of Cytokines For Higher Stability, The Cytokines And Encoding Nucleic Acid Molecules	2,498,319 Based on PCT/IB2003/004347	09/08/03 (PCT)	Pending – Awaiting 1 st Official Action <i>National Phase of PCT/IB03/004347</i> 2009 Renewal Fee (6 th Year) Deadline: 09/08/09 Request for Examination Filed 9/10/2007 (claims 1-374) 08/19/08 – Fax from FA Acknowledging Instructions regarding Maintenance Fee Instructions, Confirm Status of Claims and Examination 08/18/08 – Letter from FA Confirm Status of Claims and Examination 08/14/08 – Letter to Client advising a further Voluntary Submission of Information

PATENT

REEL: 023045 FRAME: 0273

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				Filed
US-PRV	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	60/410,258	09/09/02 (SMALL)	EXPIRED PROVISIONAL
US-PRV	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	60/457,063	03/21/03 (SMALL)	EXPIRED PROVISIONAL
US-PAT	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	10/658,355 PUBLICATION NO. US-2005-0202438- A1 DATE 09/15/05	09/08/03 (SMALL)	PENDING APPEAL BRIEF DUE 05/16/09; DROP 10/16/09 03/24/09 - Return Receipt Postcard Received for Notice of Appeal 03/16/09 - Filed Notice of Appeal 03/05/09 - Email and Letter to Client Urgent Reminder Requesting Instructions and Required Retainer for Response to Final Office Action 02/13/09 - Email and Letter to Client 3 rd Reminder Requesting Instructions and Required retainer for Response to Final Office Action 01/12/09 - Email and Letter to Client 2 nd Reminder Request Instructions and Retainer for Response to Final Office Action 12/02/08 - Email and Letter to Client Reminder Request Instructions and Retainer for Response to Final Office Action 09/19/08 - Letter to Client Forward Final Office Action Due 12/16/08, Drop 03/16/09, Request Retainer 09/18/08 - PTO Mailed Office Action due 12/16/08, Drop 03/16/09
US-CON	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	11/196,067 PUBLICATION NO. US-2006-0020396- A1 DATE: 01/26/2006	08/02/05 (LARGE)	Pending - Awaiting 1st Office Action 04/16/09 - Letter to Client Reporting Filing of Amendment and Response to Notice to Comply with Requirements 04/10/09 - Filed Amendment and Response to Notice to Comply with Requirements

PATENT

REEL: 023045 FRAME: 0274

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				02/20/09 – Email and Letter to Client Forward Filing Receipt 02/10/09 - PTO Mailed Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Due 04/10/09; Drop 08/10/09
WO-PAT	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	PCT/IB03/04255 PCT Publication No. WO 2004/022747 Priority Appln Nos. 60/410,258 60/457,063	09/08/03 PCT Publication Date 3/18/04 Priority Dates 09/09/02 03/21/03	PCT Completed – Corresponding Filings in EUROPE and CANADA
EP-PAT	Rational Directed Protein Evolution Using Two-Dimensional Rational Mutagenesis Scanning	003748392.2 Based on PCT/IB03/004255 Priority Appln Nos. 60/410,258 60/457,063	09/08/03 (PCT) Priority Dates 9/09/02 3/21/03	Notice of Appeal Deadline: 04/26/09 (Final) Regional Phase of PCT/IB03/004255 Statement Setting Out Grounds of Appeal Deadline: 06/26/09 (Final) after Notice of Appeal is Filed 2009 Renewal Fee (7th Year) Deadline: 09/30/09 EPO Decision to Refuse Issued 2/16/2009 following withdrawal of Oral Proceedings and No Response Filed 04/21/09 – Client letter stating please proceed with instructions to FA to file Notice of Appeal due by 4/26/09. 04/06/09 – Client letter advising of Notice of Appeal Deadline of 04/26/09 (Final); Statement of Appeal Deadline is 06/26/09 (Final); Requesting Instructions by 04/20/09; Copies Enclosed 02/19/09 – Email from FA Reporting Refusal of Request for Oral Instructions; Requesting Instructions to File Notice of Appeal Before 04/26/09 01/27/09 - Email from FA Withdrew Request for Oral Proceedings 01/21/09 – Final reminder to Client- advising NO action will be taken absent

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				retainer fees. Requesting instructions regarding Summons/Oral Proceedings 12/19/09 – Reminder to Client requesting instructions regarding Oral Proceedings Re-Scheduled Oral Proceedings 02/03/09; Deadline for Submissions 01/02/09 09/23/08 – Letter from FA (Confirmation Copy) Forward Summons to Oral Proceedings set 11/06/08, Final Date for Submissions 10/06/08 09/22/08 – Fax from Client Instructions - Do Not File a Response and Abandon Application in Europe (Confirmation Copy Received 10/24/08)
CA-PAT	Rational Directed Protein Evolution Using Two-Dimensional Mutagenesis Scanning	2,498,284 Based on PCT/IB03/004255 Priority Appln Nos. 60/410,258 60/457,063	09/08/03 (PCT) Priority Dates 9/09/02 3/21/03	Pending – Awaiting 1st Official Action National Phase of PCT/IB03/004255 2009 Renewal Fee (6th Year) Deadline: 09/30/09 Request for Examination Filed 6/20/2007 (Claims 1-79) 08/29/08 – Fax from FA confirming 2008 maintenance fee paid (Confirmation letter received 09/10/08) 08/21/08 – Fax from FA advising voluntary submission of prior art filed. Advising Claims 1-79 are pending. (Confirmation letter received 08/26/08).
US-PRV	Modified Interferon-B (Ifn-B) Polypeptides	60/787,208	03/28/06	EXPIRED PROVISIONAL
US-PAT	Modified Interferon-B (Ifn-B) Polypeptides	11/729,267 U.S. PUBLICATION NO.: US-2008-0038224- A1 PUBLICATION DATE 2/14/08	3/27/07	Pending Office Action Deadline: 02/28/09; Drop 05/28/09 03/23/09 – Email and Letter to Client (HanAll) Second Reminder Requesting Instructions for Response to Office Action Final Deadline 05/28/09 02/18/09 – Reminder Email and Letter to Client Request Instructions and Required Retainer to File Response to Office Action 12/04/08 – Email and Letter to Client Forward Office Action

PATENT

REEL: 023045 FRAME: 0276

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-DIV	Modified Interferon-B (Ifn-B) Polypeptides	11/729,266 PUBLICATION NO. US2008-0003202 A1 DATE: 01/03/08	3/27/07	11/28/08 - PTO Mailed Office Action Due 02/28/09; Drop 05/28/09 Priority to 60/787,208 PENDING - Non-Final Office Action Dated 4/16/09 Response Due 5/16/09; Drop 10/16/09 04/16/09 - Non-Final Office Action issued 5/16/08 - Letter to Client Reporting Notice of Acceptance of POA 5/8/08 - PTO Mailed Notice of Acceptance of POA Priority to 60/787,208
WO-PAT	Modified Interferon-B (Ifn-B) Polypeptides	PCT/EP2007/0027 00 PCT Publication No WO2007/110231 Priority Appln US 60/787,208	3/27/07 PCT Publication Date 10/4/07 Priority Date 3/28/06	PCT COMPLETED NO Corresponding national/regional phase application filed IPRP Completed: 8/29/2008 31-Month Entry Deadline: 10/28/2008 Final Deadline For Entry/Reinstatement In Europe: 02/04/09 01/13/09 - Final reminder to Client requesting instructions 12/04/08- Email to Client advising of Communication from EPO. Advising any filing in Europe for PCT must be entered by 02/04/09. Requesting instructions 12/04/08 - Email from FA Status of Entering EP Phase 12/04/08 -Email from FA attaching a further processing notice from EPO 10/24/08 - Email from Client Instructions acknowledging option 10/23/08 -Email to Client advising a notice will be sent setting a date for reinstatement of the application in Europe. Client to notify as soon as received
US-PRV	Modified Growth Hormones	60/625,652	11/04/04 (FILED LARGE)	EXPIRED PROVISIONAL

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-PROV	Modified Growth Hormones	60/706,697	08/08/2005	EXPIRED PROVISIONAL – Utility filed 06/26/2006
US-PAT	Modified Growth Hormones	11/267,871 CORRECTED PUBLICATION NO. US-2007-0249532- A9 DATE: 10/25/07 PUBLICATION NO. US-2006-0094655- A1 DATE: 05/04/06	11/03/05 (FILED LARGE)	Pending – Response to Office Action Deadline: 03/04/09; Drop 06/04/09 04/02/09 – Email and Letter to Client 2 nd Reminder Request Instructions for Response to Office Action 02/13/09 – Email and Letter to Client Request Instructions and Required Retainer for Response to Office Action 12/09/08 – Letter to Client Forward Office Action 12/04/08 - PTO Mailed Office Action Due 03/04/09; Drop 06/04/09 Application Filed 11/3/05 Priority to 60/625,652
US-CON	Modified Growth Hormones	11/476,173 CORRECTED PUBLICATION NO. US-2008-0026993- A9 DATE: 01/31/08 PUBLICATION NO. US-2006-0247170- A1 DATE 11/2/2006	6/26/06	Pending Response to Non-Final Office Action Deadline: 03/09/09, Drop 06/09/09 04/02/09 – Email and Letter to Client 2 nd Reminder Request Instructions for Response to Office Action 03/03/09 – Email and Letter to Client Reminder Request Instructions and Required Retainer for Response to Office Action 12/18/08 – Email and Letter to Client Forward Office Action Due 03/09/09, Drop 06/09/09; Request Instructions and Retainer 12/09/08 - PTO Mailed Non-Final Office Action Due 03/09/09, Drop 06/09/09 Continuation of Application No. 11/267,871 Filed On 11/3/05 (925)

PATENT

REEL: 023045 FRAME: 0278

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
WO-PAT	Modified Growth Hormones	PCT/IB2005/003662 2 PCT Publication Date 5/11/06 WO2006048777 Priority Applns US 60/625,652 US706,697	11/4/05 PCT Publication Date 5/11/06 Priority Dates 11/04/04 08/08/05	PCT COMPLETED Corresponding Filings in EUROPE, CANADA, SOUTH KOREA, AUSTRALIA, JAPAN, INDIA, CHINA, SINGAPORE, RUSSIA, INDONESIA
CA-PAT	Modified Growth Hormones	2,586,389 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending – Awaiting 1st Official Action National Phase of PCT/IB05/003662 2009 Renewal Fee (4th Year) Deadline: 11/4/09 Request for Normal Examination Filed: 10/09/07 (Claims 1-78) 11/07/08 – Letter from FA Paid 2008 Maintenance Fee due 11/04/08 per standing instructions to keep pendency of application, Next Maintenance Fee due 11/04/09 10/28/08 – Email from Client instructing defer to pay the 2008 annuity and take advantage of the one-year grace period National Phase Application of PCT/IB2005/003662
EP-PAT	Modified Growth Hormones	05807713.2 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending – Awaiting 1st Official Action Regional Phase of PCT/IB05/003662 2009 Renewal Fee (5th Year) Due: 11/04/09 04/16/09 – Attorney instructions to FA to reinstate and pay late 2008 renewal fee by 5/31/2009 deadline per client instructions 4/10/09; awaiting formal reinstatement/2008 renewal payment from FA 04/10/09 - Client Reply to Letter Dated 03/27/09 Providing Instructions to Reinstate Application and Pay Renewal and Late Fees before 05/31/09 04/10/09 – E-mail from Client Requesting to Reinstate Application Before

PATENT

REEL: 023045 FRAME: 0279

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				Deadline; Sending Signed Instructions 03/26/09 – Letter to Client Advising 2008 Renewal Fee (4th Year) Due Date Expired and is Now Due (with 6-Month Grace Period) on 05/31/09; Requesting Instructions Regarding Same by 04/30/09 02/26/09 – Email to Client Urgent Reminder Deadline for 2008 Renewal and Late/Reinstatement Fees is 05/31/09; Client Instructions and Payment Due by 05/15/09 02/13/09 - Letter from FA Notice from EPO Annual Renewal Fee Due 11/30/08 Not Paid; Still Able to Pay Until 05/31/09 with Additional Fee - Otherwise Deemed Withdrawn; Request Instructions (Confirmation Copy Received 02/25/09) National Phase Application of PCT/IB2005/003662
KR-PAT	Modified Growth Hormones	10-2007-7012644 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending - Awaiting 1st Official Action National Phase of PCT/IB05/003662 Request for Examination & Voluntary Amendment Filed 2/12/08 (amended claims 1-71) Annuitities not due in South Korea until after Grant 03/20/08 – Letter to Client Reporting Further Amendments as Filed 03/11/08 – Fax from FA Confirming Transfer to BBL; Status: Awaiting 1st OA 03/11/08 – Letter to Client Reporting Filing of Requestuets for Examination On 2/12/2008 03/06/08 – Letter to FA Regarding Transfer to BBL and Forwarding Copy of IPRP 03/05/08 – Fax from FA Confirming Transfer to BBL 02/29/08 – Fax from FA Confirming Filing of Request for Exam On 2/12/2008; Amended Claims 1-71 Now Pending National Phase Application of PCT/IB2005/003662

PATENT

REEL: 023045 FRAME: 0280

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
AU-PAT	Modified Growth Hormones	2005300257 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending National Phase of PCT/IB05/003662 Deadline for Acceptance; 3/11/2010 (Final: 12/11/2010) 1st Examiner's Report Issued 03/11/09; Response/Amendment due before acceptance deadline Renewal Fees in Australian payable annually beginning 6th Year: First Renewal Fee (6th Year) Due Date: 11/4/2010 Request for Examination Filed 9/27/07 (amended claims 1-80) 03/23/09 - Fax from FA Examiner's Report and Analysis - Nominal Deadline 03/11/10; Request Instructions Before 09/11/09 03/23/09 - Letter to Client First Examiner's Report Issued 03/11/09, Copy Enclosed; Nominal Deadline for Placing Application in Order for Acceptance Due 03/11/10; Request Instructions for Response to First Examiner's Report by 08/11/09 04/28/08 - Letter to Client Reporting IPRP and Status; Status: App in Good Order 04/28/08 - Fax from FA Confirming Transfer to BBL and Status; Status: Awaiting Issuance of Examiner's Report 03/06/08 - Letter to FA Regarding Transfer to BBL and Forwarding Copy of IPRP 09/28/07 - Letter to Client re Request Exam Filed 9/27/2007; Claims 1-80. 09/27/07 - Letter from Spruson re Request for Exam Lodged; Requested Postponement of Acceptance. 09/24/07 - Letter to Sprusons w/ Instructions to File Request for Exam Before Direction or 5-Year Deadline 11/4/2010 Per Client Directions 9/18/2007. 09/10/07 - Letter to Client re Formal Filing Report & Filing Receipt. 06/07/07 - Letter from FA Enclosing Filing Receipt; and Providing General Information re Request for Examination, Renewal Fees, and Assignments

PATENT

REEL: 023045 FRAME: 0281

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				05/23/07 – Letter from FA re Filing Particulars and Enclosing National Phase Entry Request and Preliminary Amendment; and Confirming That Electronic Copy of Sequence Listing Has Been Lodged 05/18/07 - Letter to Client re Application Filed 5/17/2007; Initial Report. 05/17/07 – Letter from FA Confirming That National Phase Entry Was Filed Today. 04/27/07 - Letter to FA Forwarding CD Versions of PCT Application as Filed, Including Sequence; New Claims 1-80 for Filing; Also Confirm Nautilus is A French Company. 04/24/07 – Letter from FA re Confirmation of Instructions; Will File by Deadline of 06/04/07 04/23/07 - Letter to FA w/ Instructions to File Natl Application Due 6/4/2007 (31-Month); Also New Claims for Filing. National Phase Application of PCT/IB2005/003662
JP-PAT	Modified Growth Hormones	2007-539656 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending - Awaiting 1st Official Action National Phase of PCT/IB05/003662 Request for Examination Filed 9/26/07 (amended claims 1-75) Annuities in Japan not due until after Grant 06/19/08 – Letter to Client Reporting Japan Application Was Laid Open for Public Inspection On 06/05/08 Under Publication No. 2008-518615a 06/12/08 – Fax from FA Reporting That App Was Laid Open Under 2008-518615a On 6/5/2008 National Phase Application of PCT/IB2005/003662
IN-PAT	Modified Growth Hormones	04051/DELNP/2007 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending – Awaiting 1st Official Action National Phase of PCT/IB05/003662 Request for Examination/Formalities Filed 11/5/07 (amended claims 1-75) Annuities in India not due until after Grant

PATENT

REEL: 023045 FRAME: 0282

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				05/29/08 – Fax from FA Confirming Filing of Form 3 and List of Docs from Corresponding Apps (ongoing disclosure requirement) 04/29/08 – Fax from FA Confirming That IPRP Was Submitted to The Patent Office National Phase Application of PCT//IB2005/003662
CN-PAT	Modified Growth Hormones	200580045437.6 Based on PCT//IB05/003662	11/04/05	Pending – Awaiting 1st Official Action National Phase of PCT//IB05/003662 Request for Examination Filed 9/14/07 (amended claims 1-75) Annuities in China not due until after Grant 03/10/08 – Fax from FA Confirming Transfer to BBL; Status: 1st OA to Be Issued in About 30 Months 03/06/08 – Letter to FA Regarding Transfer to BBL and Forwarding Copy of IPRP 03/05/08 – Fax from FA Confirming Transfer to BBL; HK Registering Due 6/26/2008; Voluntary Amendments Due 4/26/2008 03/05/08 – Letter to FA Regarding Transfer to BBL w/Instructions to Not to Record in HK or File Voluntary Amendments 02/20/08 – Fax from Client with Instructions to Not Amend Application. 01/16/08 – Fax from FA Indicating That App Was Published On 12/26/2007 Under Cn 101094865a; HK Recording Due 6/26/2008; Voluntary Amendments Due 4/26/2008 National Phase Application of PCT//IB2005/003662
SG-PAT	Modified Growth Hormones	200703250-1 Based on PCT//IB05/003662	11/04/05 (PCT)	Pending – Awaiting Final Exam Report National Phase of PCT//IB05/003662 to be ABANDONED re no Response to Examination Report Filed by 2/28/2009 deadline

PATENT

REEL: 023045 FRAME: 0283

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				Deadline for Grant Fees/Voluntary Amendment: 05/04/09 Annuities in Singapore not due until after Grant 03/04/09 - Fax from FA Absence of Instructions Did Not Respond to Written Opinion; Application Not Refused - End of Exam Process and Final Exam Report Will Contain Comments as Written Opinion 02/27/09 - Reminder Fax from FA Requesting Instructions for Response to Written Opinion by 02/28/09 (FINAL) 02/16/09 - Fax from FA Request Instructions Written Opinion Response Due 02/28/09 (Inextendible); No Response Application Not Refused (Confirmation Copy Received 03/02/09) 02/04/09 - Letter to Client Urgent Request for Instructions and Payment for Response to Written Opinion by 02/23/09; Deadline 02/28/09 (FINAL) 02/03/09 - Fax from FA Inextendible Due Date 02/28/09 - Request Instructions ASAP (Confirmation Copy Received 02/13/09) 01/29/08 - Filed Request for Combined Search/Exam Report (Claims 1-72) National Phase Application of PCT/IB2005/003662
RU-PAT	Modified Growth Hormones	2007120182 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending – Awaiting 1st Official Action <i>National Phase of PCT/IB05/003662</i> Request for Examination & Additional Exam Fees Paid 11/15/07 (claims 1-80); request to examine all parts (all independent claims) 06/19/08 – Letter to Client Reporting Status of Application. 05/22/08 – Fax from FA Reporting Request for Exam as Filed
ID-PAT	Modified Growth Hormones	W00 2007 01382 Based on PCT/IB05/003662	11/04/05 (PCT)	Pending – Awaiting 1st Official Action <i>National Phase of PCT/IB05/003662</i> Request for Examination Filed 9/27/07 (amended claims 1-75) Annuities in Indonesia not due until after Grant

PATENT

REEL: 023045 FRAME: 0284

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				07/30/08 - Fax from FA Informing PCT IPRP Filed with Indonesian Patent Office 04/02/08 - Fax from FA Confirming Transfer to BBL; Status: Application National Phase Application of PCT/IB2005/003662
US-PRV	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	60/678,031	05/04/05 (FILED LARGE)	EXPIRED PROVISIONAL
US-PRV	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	60/733,835	11/04/05 FILED LARGE	EXPIRED PROVISIONAL
US-PAT	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	11/429,100 PUBLICATION NO. US-2006-0251619-A1 DATE 11/09/2006	05/04/06 (FILED LARGE)	ABANDONED
WO-PAT	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	PCT/IB2006/00203 4 PCT Publication No. WO2006120580 Priority Appln Nos. 60/678,031 60/733,835	05/04/06 Publication Date 11/16/06 Priority Dates 5/4/2005 11/4/2005	PCT COMPLETED Corresponding Filings in EUROPE , CANADA and SOUTH KOREA IPRP Completed 11/6/2007 (PCT claims 1-120)
EP-PAT	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	06765642.1 Based on PCT/IB06/002034	05/04/06 (PCT)	Pending - Awaiting 1 st Official Action Regional Phase of PCT/IB06/002034 To be ABANDONED per client instructions 4/10/2009; attorney instructions

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				to FA 4/17/2009 re non-payment of 2009 renewal fee 2009 Renewal Fee (4th Year) Due: 5/31/09 Reinstatement & Late 2009 Renewal Fee Deadline: 11/30/2009 4/17/09 – Attorney Instructions to FA re non-payment of 2009 renewal fee and note for reinstatement reminder; letter to client re same and deadline for reinstatement in Europe 04/10/09 – Client Instructions re NOT Pay 2009 Renewal Fee and Allow Provisional Abandonment; request for reinstatement due date 04/10/09 – E-mail from Client Decision to Abandon Application; Requesting Further Reinstatement Reminder; Sending Signed Instructions 03/26/09 – Letter Reminder to Client Advising 4th Year Renewal Fee Due 05/04/09; Requesting Instructions Regarding Same by 04/04/09; Advising Application in Abeyance and Request for Examination Due 05/04/11 02/18/09 – 02/04/09 - First Renewal Reminder Fee Due 05/31/09; Request Instructions 02/04/09 – Letter to Client Requesting Instructions and Payment for 2009 Renewal Fee (4th Year) by 04/04/09; Deadline: 05/04/09 02/04/09 - First Renewal Reminder Fee Due 05/31/09; Request Instructions
CA-PAT	Modified Polypeptides And Methods For Using Modified Polypeptides Interferon-Gamma Interferon-Gamma	2,607,806 Based on PCT/IB06/002034	05/4/06 (PCT)	Pending National Phase of PCT/IB06/002034 To be ABANDONED per client instructions 4/10/2009; attorney instructions to FA 4/17/2009 re non-payment of 2009 renewal fee 2009 Renewal Fee (3rd Year) Due: 5/4/09 Reinstatement & Late 2009 Renewal Fee Deadline: 5/4/2010 Request for Examination Deadline: 5/4/2011 4/17/09 – Attorney Instructions to FA re non-payment of 2009 renewal fee and note for reinstatement reminder; letter to client re same and deadline for reinstatement in Canada, as well as request for examination in order to continue with prosecution

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				04/10/09 - Client Instructions NOT Pay 2009 Renewal Fee and Allow Provisional Abandonment; request for reinstatement due date 04/10/09 - E-mail from Client Decision to Abandon; Requesting Further Reinstatement Reminder; Sending Signed Abandonment Instructions
KR-PAT	Modified Interferon-Gamma Polypeptides And Methods For Using Modified Interferon-Gamma Polypeptides	10-2007-7028338 Based on PCT/IB06/002034	05/04/06 (PCT)	Pending Request for Examination Deadline: 5/4/2011 (Final) Voluntary Amendment Filed 12/17/07 (amended claims 1-116) Annuities not due until after Grant in South Korea 08/21/08 - Letter to Client requesting instructions regarding Request for Examination- deadline 05/04/11 03/13/08 - Fax from FA Regarding Status: Request for Exam Due 5/4/2011;
US-PRV	Modified Glucagon-Like Peptide-1 Polypeptides And Uses Thereof	61/011,619	1/17/08	EXPIRED PROVISIONAL
US-PRV	Modified Erythropoietin Polypeptides And Use Thereof For Treatment	60/861,615	11/28/06	EXPIRED PROVISIONAL
US-PAT	Modified Erythropoietin Polypeptides And Use Thereof For Treatment	11/998,387	11/28/07	PENDING - AWAIT FIRST OFFICE ACTION 04/16/09 - PTO Mailed Status Update Application will Receive Office Action in Approximately 8 Months 03/26/09 - PTO Mailed Updated Filing Receipt 03/26/09 - PTO Mailed Notice of Acceptance of POA 02/27/09 - Email and Letter to Client Reporting Filed Response to Missing Parts and Official Filing Receipt
WO-PAT	Modified Erythropoietin Polypeptides And Use Thereof For Treatment	PCT/GB2007/0045 20	11/27/2007	Pending - 30-Month National/Regional Phase Deadline: 05/28/09 (Final)

PATENT

REEL: 023045 FRAME: 0287

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
		PCT Publication No. WO 2008/065372 Priority Appln: 60/861,615	PCT Publication Date 6/5/2008 Priority Date 11/28/06	31-Month National/Regional Phase Deadline: 06/28/09 ISR/Written Opinion Issued (ISA/EP) 8/22/2008; NO PCT Demand/Response Filed; PCT 1-196; ISR Published 10/23/2008 4/17/08 – Further Client reminder re 30-month deadline and request for instructions 11/14/08 –Letter to Client enclosing copy of International Search Report. 30-month National Phase Entry deadline: 05/28/09. Requesting instructions and payment by 03/29/09
AR-PAT	Modified Erythropoietin Polypeptides And Use Thereof For Treatment	07 01 05270 Priority Appln: 60/861,615	11/28/07 Priority Date 11/28/06	Pending Request for Examination Deadline: 11/28/2010 Annuities not due until after Grant in Argentina AR claims 1-204 filed on entry 12/12/08 – Emailed from FA advising reply for the 178 resolution regarding the priority document filed on 10/29/08 (Confirmation Copy Received 01/02/09) 09/04/08 – Letter to Client advising Response to Resolution P-178-0 filed with Argentine Patent Office. Requesting instructions regarding Examination 09/04/08 – Email from FA advising deadline to request Examination 11/28/2010.
GC-PAT	Modified Erythropoietin Polypeptides And Use Thereof For Treatment	2007/9559 Priority Appln: 60/861,615	11/27/07 Priority Date 11/28/06	ABANDONED re non-payment of 2009 Renewal Fee 2009 Renewal Fee (3rd Year) Deadline: 03/31/09 (Final); Client instructions to abandon 3/24/09 Claims 1-204 for Filing/Entry in the GCC 03/28/09 - Email from FA Confirm No Further Action Taken, Allowed to Go Abandoned 03/24/09 – Letter to Client confirming Abandonment Instructions and communicated to FA; Copy of Instruction Letter Enclosed 03/24/09 – Letter to FA Do Not Effect Payment of 2009 Renewal Fee and Allow

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
US-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	11788,836	04/19/07	Application to Become Abandoned 03/24/09 - E-mail from Client Requesting to Abandon Application; Enclosing Letter Dated 03/24/09 with Instructions 02/26/09 - Letter to Client Urgent Reminder Requesting Instructions and Payment for 2009 Renewal Fee Due 03/31/09 (FINAL) PENDING -AWAIT OFFICE ACTION 03/10/09 - Return Receipt Postcard Received for Election and Preliminary Amendment 03/03/09 - Email and Letter to Client Forward Election and Preliminary Amendment Filed 02/26/09 - Filed Election and Preliminary Amendment 01/26/09 - PTO Mailed Restriction Requirement Due 02/26/09; Drop 07/26/09
AU-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	2007201663 (first filing)	04/16/07	Pending Deadline for Acceptance: 7/03/09 (Final: 4/3/2010) 1st Examiner's Report Issued: 7/03/08 Renewal Fees in Australian payable annually beginning 6th Year: First Renewal Fee (6th Year) Due Date: 4/16/2012 Request for Normal Examination Filed: 05/23/07 (claims 1-50) 04/06/09 - Reminder Letter from FA Advising Response to Examiner's Report Due 07/03/09, 04/03/10 (Final); Requesting Instructions Regarding Same 01/05/09 - Letter from FA Reminder Response to Examiner's Report Due 07/03/09, Request Instructions 08/07/08 - Letter to Client requesting instructions to 1st Examination Report and retainer check. 08/07/08 - Fax from FA Attaching Copy of Examination Report-Initial Deadline for Acceptance: 07/03/09 Final Deadline: 04/03/2010. (Confirmation letter received 08/11/08).

PATENT

REEL: 023045 FRAME: 0289

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
AR-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	070103607 (re-filed) Priority Original AR Filing 070101663 Filed: 18 April 2007	08/14/07	Pending – Awaiting 1st Official Action Request for Substantive Examination Filed: 11/12/07 (claims 1-46) Annuities not due in Argentina until after Grant 12/24/08 – Email from FA Filed 178 Resolution Regarding Priority Document on 10/29/08 12/12/08 – Email from FA advising reply for the 178 resolution regarding the priority document filed on 10/29/08 (Confirmation Copy Received 01/02/09) ABANDONED 04/20/09 – Client instructions to allow application to become irrevocably abandoned 04/14/09 – Letter to client confirming instructions re abandonment; note reinstatement deadline 1/17/2010 (2009 renewal fee) and request for instructions; also request for exam due by 4/19/2010 04/14/09 - E-mail from FA Advising 3rd Year Annuity Deadline is 07/20/09 (Extendible 6 Months Until 01/20/10); Requesting Instructions Regarding Same 4/13/09 – Attorney Instructions to FA re non-payment of 2009 renewal fee and note for reinstatement reminder; further instructions to follow regarding prosecution/examination 04/10/09 - Client Reply to Letter Dated 04/10/09 Providing Instructions to NOT Pay 2009 Renewal Fee and Allow Application to be Provisionally Abandoned
BR-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	0705943-4 (first filing)	04/19/07	
CA-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	2583716 (first filing)	04/18/07	Pending – Awaiting 1st Official Action 2010 Renewal Fee (3rd Year) Deadline: 04/18/2010 Request for Normal Examination Filed: 07/11/07; Voluntary Amendment Filed 3/28/2008 (amended claims 1-46) 04/10/09 - Client Reply to Letter Dated 04/09/09 Providing Instructions to Pay 2009 Renewal Fee 04/10/09 – E-mail from Client Retaining Application; Sending Signed Instructions 04/10/09 – E-mail from Client Advising Signed Instructions Regarding 2009

PATENT

REEL: 023045 FRAME: 0290

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				Renewal Fee Being Sent 04/08/09 – Letter to FA Providing Instructions to Proceed with Payment of 2009 Renewal Fee (2nd Year) per attorney directions 04/03/09 - Fax Reminder from FA Requesting Instructions for Maintenance Fee Due 04/18/09 03/25/09 – Letter to Client Renewal Fee Due 04/18/09; Request Instructions and Retainer by 04/08/09
CL-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	1098-2007 (first filing)	04/18/07	Pending – Awaiting 1st Official Action Examiner's Fee paid 2/22/2008 (claims 1-46) Annuities not due in Chile until after Grant Claims 1-46 for Filed on Entry in Chile and publication in Gazette on 10/5/2007 (preliminary formalities/opposition) 05/28/08 – Letter to Client Reporting Payment of Examiner's Fee 03/26/08 – Fax from FA w/ Confirmation of Payment of Examiner's Fee
KR-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	10-2007-0038557 (first Filing)	04/19/07	Pending Outstanding 1st Official Action Issued 12/24/2008 RESPONSE due by 4/24/2009 (initial due date of 2/24/2009; Extendible up to 4 months; Final Due Date: 6/24/09) Request for Examination & Amendment Filed 8/7/2007 (claims 1-52) Annuities not due in South Korea until after Grant 04/17/09 – Attorney instructions to FA to request one-month extension (3rd request) of time to respond from 4/24/2009 until 5/24/2009 04/07/09 – Letter to Client Analysis of 1st Official Action Response Due 04/24/09; Requesting Instructions and Retainer 03/27/09 - Email from FA Analysis of Notice of Preliminary Rejection, Response Due 04/24/09 (Extendable); Request Instructions 03/19/09 – E-mail from FA Forwarding English Translation of Preliminary

PATENT

REEL: 023045 FRAME: 0291

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
				Rejection, Notice of Preliminary Rejection and Cited References; Response Due 04/24/09 (Further Extendable for Two Months) 03/13/09 - Fax from FA Confirming Due Date Extended to 04/24/09; Request Instructions 03/09/09 -- Letter to FA Instruction Request Further One-Month Extension of Time to 04/24/09 02/26/09 -- Letter to Client Requesting Payment and Instructions for 1st Official Action Due 03/24/09; 06/24/09 (FINAL)
MX-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides	MX/A/2007/004822 (first filing)	04/19/07	Pending - Awaiting 1st Official Action Claims 1-46 filed on entry for examination Annuities not due in Mexico until after grant 01/24/08 -- Letter from Clarke re Voluntary Amendment Has Been Filed. 01/04/08 -- Letter from Clarke re Amendment - Requesting Attachments Be Re-Sent
UY-PAT	Oral Dosage Formulations Of Protease Resistant Polypeptides Mutants	30.293 (first filing)	04/18/07	Pending - Awaiting 1st Official Action Request for Publication & Examination Filed: 9/18/2007 (claims 1-46) Annuities not due in Uruguay until after grant Claims 1-46 for Filed on Entry in Uruguay 05/30/08 -- Letter to Client Reporting Filing of Voluntary Amendment 01/31/08 -- E-mail from FA re Amendments Filed On 1/11/08.
US-PRV	Protease Resistant Superleads Of E41q- Prov.			PENDING - AWAITING AUTHORIZATION TO FILE 03/17/09 -- Email from Hannall -- Application Very Important; Request Filing in the Course of This Week 03/17/09 -- Email to Hannall -- Draft Application, Never Received Authorization to File; Still Possible to File Application -- Obtained French Foreign Filing License; Can Be Filed

PATENT

REEL: 023045 FRAME: 0292

Country	TITLE	Serial No. (Patent No.)	File Date (Issued)	STATUS / COMMENTS
	Superleads Of Erythropoietin (Epo) That Exhibit Protease Resistance	61/130,376	05/20/08	PENDING PCT/Utility Filing Deadline: 05/29/09; Client Instructions Due 04/29/09 03/06/09 – Email and Letter to Client Requesting Instructions and Required Retainer for PCT/Utility and Non-PCT Countries Filing Deadline of 05/29/09; Instructions Due by 04/29/09
FRANCE	Méthodes de criblage ou d'évaluation de la performance d'un ensemble d'agents biologiques dans des cellules cibles vivantes	99 15884	16/12/1999	DELIVRED on 08/03/2002
UNITED STATES	Procédé de détermination du titre d'agents biologiques en temps réel dans des cellules cibles vivantes et ses applications	11 412,939	28/04/2006	DELIVRED on 25/03/2008
FRANCE	Procédé de détermination du titre d'agents biologiques en temps réel dans des cellules cibles vivantes et ses applications	0005852	09/05/2000	DELIVRED on 02/08/2002